American Portfolios Advisors’s Galectin Therapeutics GALT Stock Holding History

American Portfolios Advisors’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.68K	Hold	1,031	–	–	﹤0.01%	3173
2022 Q2	$1.35K	Hold	1,031	–	–	﹤0.01%	3219
2022 Q1	$1.66K	Hold	1,031	–	–	﹤0.01%	3269
2021 Q4	$2.13K	Hold	1,031	–	–	﹤0.01%	3154
2021 Q3	$4K	Hold	1,031	–	–	﹤0.01%	2945
2021 Q2	$3.3K	Hold	1,031	–	–	﹤0.01%	2991
2021 Q1	$2.24K	Hold	1,031	–	–	﹤0.01%	2964
2020 Q4	$2.31K	Hold	1,031	–	–	﹤0.01%	2666
2020 Q3	$2.75K	Hold	1,031	–	–	﹤0.01%	2491
2020 Q2	$3.15K	Hold	1,031	–	–	﹤0.01%	2395
2020 Q1	$2.02K	Hold	1,031	–	–	﹤0.01%	2398
2019 Q4	$2.95K	Hold	1,031	–	–	﹤0.01%	2463
2019 Q3	$3.78K	Buy	1,031 +500	+94%	+$1.81K	﹤0.01%	2288
2019 Q2	$2.2K	Buy	+531	New	+$2.3K	﹤0.01%	2451

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

American Portfolios Advisors's GALT Position: Q3 2022 in Review

American Portfolios Advisors held its Galectin Therapeutics (GALT) position steady in Q3 2022 at 1,031 shares worth $1.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3173.

American Portfolios Advisors first reported a position in GALT in Q2 2019 and has held it in 14 quarters since. The position peaked at $4K in Q3 2021. 59 funds tracked by Wall St. Rank hold GALT as of Q3 2022.

American Portfolios Advisors held 1,031 shares of Galectin Therapeutics worth $1.68K as of Q3 2022.
American Portfolios Advisors left its Galectin Therapeutics share count unchanged in Q3 2022.
Galectin Therapeutics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #3173 holding.
American Portfolios Advisors first reported a position in Galectin Therapeutics in Q2 2019 and has held it in 14 quarters since.
American Portfolios Advisors's Galectin Therapeutics position peaked at $4K in Q3 2021.
59 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.